Relais' Q4 report was above LSEG consensus expectations, supported by strong 9% y/y organic revenue ...
Redeye provides an update following SenzaGen’s Q4 2024 report.
Redeye provides an update following Optomed’s Q4 report.
Redeye updates its estimates and valuation following Mentice’s Q4 2024 report.
Strong EBIT of SEK 437m (ABGSCe 495m) in Q4 New targets: 15% ROE and total '25-'27 EBIT SEK 1.
Redeye endorses today’s news that the European Commission has approved Emcitate for “the treatment o...
Sales decline continued, but solid cost control, comps ease from here Cut sales by 2%, EBIT by SEK 3...
Redeye comments in Invisio’s Q4-results which were in line with the preannounced results.
Rec PTP -1% vs ABGSCe, driven by lower rental income Values largely unchanged, despite slight yield ...
Solteq’s Q4 performance mirrored its full-year trends, with declining sales but improved profitabili...
Raute’s Q4 margins were a bit lower than we estimated even if top line was higher than we expected.
CapMan’s Q4 results came with a pleasant surprise through higher than anticipated investment returns...
Adj. EBITA -11% vs ABG, -13% vs consensus Service companies drove the miss, products held up better ...
Redeye comments on a solid Q4 report in a soft market, showing that CombinedX is back among the qual...
Sales -10% vs. ABGSCe, but EBIT only -2% on better opex control GC&MP to continue growth; NW&FT, FW ...
